Bisphosphonates are a class of medications widely prescribed for conditions involving bone loss, such as osteoporosis, Paget’s disease, and metastatic cancers affecting bone. While these drugs are effective in reducing bone resorption and fracture risk, they present notable challenges in dental care. Understanding the potential complications associated with bisphosphonate use is essential for both dental professionals and patients to ensure safe and appropriate treatment planning.
The most significant dental complication linked to bisphosphonates is medication-related osteonecrosis of the jaw (MRONJ). This condition is characterized by exposed, non-healing bone in the maxillofacial region that persists for more than eight weeks. MRONJ occurs because bisphosphonates inhibit osteoclast activity, reducing the bone’s ability to remodel and heal after trauma. This risk is especially heightened following invasive dental procedures such as tooth extractions, implant placement, or periodontal surgery.
Patients receiving intravenous (IV) bisphosphonates, often used in cancer treatment, face a higher risk of developing MRONJ compared to those taking oral formulations for osteoporosis. However, it is important to note that even oral bisphosphonates can pose a risk, particularly with long-term use exceeding three to five years. Additional contributing factors include poor oral hygiene, smoking, diabetes, corticosteroid use, and pre-existing dental infections.
Preventive dental care plays a critical role in minimizing complications. Ideally, patients should undergo a comprehensive dental evaluation before initiating bisphosphonate therapy. This allows for the identification and treatment of potential sources of infection or the need for extractions prior to medication use. Once a patient is on bisphosphonates, maintaining excellent oral hygiene and scheduling regular dental check-ups become even more important.
When dental treatment is necessary for patients currently taking bisphosphonates, clinicians must carefully weigh the risks and benefits. Non-invasive procedures, such as fillings and routine cleanings, are generally considered safe. However, for invasive procedures, alternative treatment options should be explored when possible. For example, endodontic therapy may be preferred over extraction to preserve the tooth and avoid bone exposure.
In some cases, a “drug holiday” may be considered, particularly for patients on long-term oral bisphosphonate therapy. This involves temporarily discontinuing the medication prior to invasive dental procedures to potentially reduce the risk of MRONJ. However, this decision must be made collaboratively with the patient’s physician, as stopping bisphosphonates may increase the risk of fractures or other complications related to their underlying condition.
Patient education is another essential component of care. Individuals taking bisphosphonates should be informed about the importance of disclosing their medication history to their dental provider and reporting any symptoms such as jaw pain, swelling, or exposed bone. Early detection of MRONJ can improve outcomes and may allow for more conservative management.
In conclusion, while bisphosphonates provide significant benefits in managing bone-related conditions, they introduce important considerations and possible complications in receiving dental care. Through preventive strategies, careful treatment planning, and interprofessional collaboration, dental professionals can help reduce the risk of complications and ensure the safest possible outcomes for their patients.
Dr. Lauren Hargrove is the dental surgeon at Hiawassee Family Dental. He is also the Lake Chatuge Living Expert Contributor for Family Dentistry. He may be contacted by phone at (706) 896-1204.
